Coparion

www.coparion.vc/en

VCMatch tracks Coparion as an investor focused on Biotech and Other companies and Germany markets. Upload your deck to compare your startup against the full private matching profile.

Check Size

Not specified

Stages

Not specified

Focus Areas

Biotech, Other

Geography

Germany

Investment Thesis

Coparion’s investment philosophy is to accelerate the growth of “young technology companies” by providing capital and strategic know‑how while explicitly avoiding interference in day‑to‑day operations. They position themselves as a long‑term, value‑focused partner that leverages “long‑standing experience in venture capital and in building companies” to “discern potentials and open up new perspectives,” and to help founders navigate difficult situations. Coparion emphasizes independence, pragmatism and steady, non‑opportunistic value creation (e.g., “All our decisions focus on increasing the value of our portfolio companies – always taking a long-term perspective bereft of any short-term opportunism.”).

Is Coparion right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

Coparion is most relevant for founders raising venture-backed rounds in Biotech and Other, especially across Germany.

Focus statement

Focus: growth capital for young technology companies — providing support through know‑how and partnership rather than operational control; they "only invest together with private investors" and prioritise shared values and quality standards.

Value Add

Non‑operational partner approach: explicitly "support entrepreneurial vision with our know‑how, but without intervening in daily business operations."
Long‑term, value‑creation orientation: decisions target increasing portfolio value and avoid "short‑term opportunism."
Co‑investment requirement: "We only invest together with private investors," indicating a deal‑sourcing and syndication discipline.
Independence and speed: asserts independence that makes them "flexible, pragmatic, and able to act swiftly."
Operational & sector expertise inside team: presence of specialists (e.g., a "scientific specialist for life science companies") indicating capability to support deep‑tech / life‑science startups.
Backed by significant capital and institutional credibility: EUR 275m AUM and institutional shareholders listed (ERP fund via Federal Ministry, KfW Capital, EIB) while maintaining an independent, private co‑investment focus.